All about Pre-filled Syringe Systems

From Initial Development to Final Fill Finish

Drug-Syringe interactions

Christa Jansen-Otten Bernd Zeiss *Gothenburg, October 19th and 20th 2023*









Overview and Introduction into Pre-filled Syringe Market *Overview & Trends • Stakeholders • User's perspective*

Technical Aspects

Syringe • Plunger • Needle • Needle shield or Tip cap • Autoinjector • Regulatory guidelines and technical standards

Overview & Introduction into Drug-Syringe Interactions Aggregation • Degeneration • Oxidation • Viscosity • Bubbles

Overview & Introduction to manufacturing Process of PFS

Syringes Barrel Forming • Washing • Siliconization • Sterilization • Regulatory guidelines and technical standards ...

Fill and Finish

Filling • Stoppering • Assembly • Technical Standards

Hands-on Session 1





Drug features and possible interactions with syringe components

- Viscosity, pH, concentration, ionic strength, buffer...
- Volume contact surface of formulation to container
- Sensitivity
 - Light
 - Oxygen
 - Temperature
 - Particles
 - Silicone oil
 - Storage
 - Vibration
 - Shear forces
 - Rubber components
 - Tungsten, glue, steel...
 - Terminal Sterilization
 - Handling in F&F, mixing, pumping




Composition of a formulation in a PFS

- API
- Water
- Buffer
- Tonicity Agent
- Surfactant
- Antioxidant
- ...






Possible Interaction of Drug Product and Elastomeric Closures







Observed Interactions of Proteins with Pharmaceutical Elastomers



Aggregation of proteins with silicone oil

Adsorption e.g. of Active Product Ingredient [API] at elastomers and container walls

Increased immunogenicity (interactions with leachables)

Out of Specifications [OOS] results for moisture content (e.g. for lyophilized products)





High Level Definitions



Extractables


- Organic & inorganic substances in packaging components which can be extracted during forced or worst-case laboratory conditions
- In theory, these substances are mobile & have the potential to leach from the packaging, but this describes an ideal scenario

Leachables

- Organic & inorganic substances that migrate from primary packaging into the final drug product when manufactured & stored under normal conditions
- > In practice, new substances may be formed by the chemical interaction of leachables & the drug product


Patient may be exposed to extractables; Patient will be exposed to leachables







Extractables & Leachables - Risks







Drug-syringe Interactions I

Bubbles

- Generated in filling process
- Less bubbles in vacuum stoppering
- Bigger bubble in vent tube stoppering
- Transport test recommended
- Moving bubble during transport
- Potential effect on drug formulation
- Expansion and plunger movement risk in air transport (CCI harmed)
- Air means oxygen





Drug-syringe Interactions II

Various interactions possible


- Aggregation e.g. with silicone oil
- Degeneration temperature, transport
- Oxidation plastic barrel, air bubble
- Adsorption barrel surface

You see

- Precipitation
- Blurring
- Nothing

Triggered by

- Drug formulation itself
- Temperature changes, light, oxygen
- Bubbles and mechanical stress
- Barrel: silicone oil, tungsten, glue, steel
- Elastomer components: cap, stopper



What can be done?

- Stability testing
- Low tungsten
- Low silicone oil
- Extractables profile of rubber components
- Coated plunger stoppers
- Reformulate or stay in vial



Drug-syringe Interactions III

Not seen in syringes - yet another benefit over vials


- pH shift
- Delamination

Why in vials, but not in syringes?

- Vial forming more stressing to glass
- Syringe inside covered by silicone oil
- More aggressive buffers and formulations filled in vials (?)
- Higher pH in vials than in PFS (?)
- PFS normally based on physiologic sodium chlorine solution

Options

- Surface treatment of vials (SiO₂, Ammonium sulphate)
- Special high resistance glass vials, delamination tested
- COP vials
- Reformulate







Minimum time period covered

Storage condition

Study



Test methods and Guidelines I

				non statute and Concept a three data of	by data at submission
PDA Technical Report 73	Dru	g-container interaction	25°C ± 2°C/60% RH ± 5% RH or 30°C ± 2°C/65% RH ± 5% RH	12 months	
	1	Quality throughout shelf life when transported and stored -	Intermediate**	30°C ± 2°C/65% RH ± 5% RH	6 months
ISO 10040-8	Ι.	stability studies	Accelerated	$40^{\circ}C \pm 2^{\circ}C/75\%$ RH $\pm 5\%$ RH	6 months
ICHQ1A	2.	The impact of components (e.g. needle, tubing)			B
	3.	Extractables/leachables , e.g residuals from forming, moldin assembly process, gluing, sterilization process, rubber ingredients, impurities and degradation products, free silicor labels	•		: Ĥ
	4.	Compatibility, e.g. loss of potency of the drug, adsorption, degradation of the drug, change of stability indicating param	neters		\square
	5.	Effect of shear forces			
	6.	Biological hazard assessment for the finished prefilled syrin following, e.g. ISO 10993-1	ige		






Test methods and Guidelines II

PDA Technical Report 73	Drug-container interaction		
ISO 10040-8	7.	The container closure system shall maintain sterility throughout its shelf life including transportation	
ICHQ1A	8.	Endotoxin levels specified	
	9.	The container closure system shall ensure integrity	

- throughout filling, terminal sterilizations, further manufacturing steps, storage and transportation to ensure content sterility and to prevent leakage
- **10. Deliverable volume** from the finished prefilled syringe shall comply with the required or labelled drug dose
- 11. Particles (visible and subvisible) see pharmacopoeias







Summary - Drug-syringe interaction

- Drug and container can interact in many ways
- Effects on syringe performance possible
- Effects on drug quality possible
- All container materials to be evaluated
- Fill and Finish Process to be investigated
- Stability and Transport studies to be carried out





Sources

- Effect of Various Silicone Oil And Tungsten Levels on the Stability of a Monoclonal Antibody in Nine Commercially Available Prefilled Syringes. Markela Ibo Murphy, Jesse A. Leissa, Sandra B. Plata, Amy L. Chamberlain, Sajal M. Patel. March 16, 2023
- https://doi.org/10.1016/j.xphs.2023.03.009
- Characterization of Subvisible Particles in Biotherapeutic Prefilled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock. Nancy Jiao, Gregory V. Barnett, Twinkle R. Christian, Nathan H. Joh, Marisa K. Joubert, Shawn Cao, November 02, 2019. https://doi.org/10.1016/j.xphs.2019.10.066
- The Impact of Syringe Age Prior to Filling on Migration of Subvisible Silicone-Oil Particles into Drug Product. Jing Song, Guangli Hu, Hassen Hamzaoui, Steven C. Persak, Hanmi Xi, Yongchao Su, September 19, 2022, DOI:https://doi.org/10.1016/j.xphs.2022.09.015
- Silicone oil induced aggregation of proteins: LaToya S. Jones, Allyn Kaufmann, C. Russell Middaugh, 25 February 2005 https://doi.org/10.1002/jps.20321
- Silicone Oil- and Agitation-Induced Aggregation of a Monoclonal Antibody in Aqueous Solution. Renuka Thirumangalathu, Sampathkumar Krishnan, Margaret Speed Ricci, David N. Brems, Theodore W. Randolph, John F. Carpenter, https://doi.org/10.1002/jps.21719
- Silicone-oil-based subvisible particles: their detection, interactions, and regulation in prefilled container closure systems for biopharmaceuticals. Flora Felsovalyi, Sébastien Janvier, Sébastien Jouffray, Hervé Soukiassian, Paolo Mangiagalli, PMID: 23023774 10.1002/jps.23328
- PDA Technical Report No. 73 (TR 73) Prefilled Syringe User Requirements for Biotechnology Applications (single user digital version)
- ISO 11040-8:2016 Prefilled syringes Part 8: Requirements and test methods for finished prefilled syringes
- ICHQ1A Stability testing of new drug substances and drug products Scientific guideline
- ISO 10993-1:2018 Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process

